FiercePharmaOriginal article
{"a":[{"_":"Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials","$":{"href":"/pharma/more-az-china-deals-kailera-hengrui-oral-glp-1-data-scrutiny-chinese-trials","hreflang":"en"}}]}
Phase 3positiveoral GLP-1 candidatePositive
AI Analysis
Summary
AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, while Hengrui and Kailera announced positive Phase 3 data for an oral GLP-1 candidate in obesity and diabetes from Chinese trials.
Clinical Trial Data
Phase
3
Outcome Details
Phase 3 data reported for oral GLP-1 candidate in obesity and diabetes from China
Importance:7/10
Sentiment:
0.60
GLP-1oral formulationobesitydiabetesChinalicensing dealpartnershipPhase 3 data
Read the original article
Published by FiercePharma on July 10, 2026 8:07 AM